| Product Code: ETC6657394 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Canada Gastrointestinal Diseases Drug Development Market Overview |
3.1 Canada Country Macro Economic Indicators |
3.2 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, 2021 & 2031F |
3.3 Canada Gastrointestinal Diseases Drug Development Market - Industry Life Cycle |
3.4 Canada Gastrointestinal Diseases Drug Development Market - Porter's Five Forces |
3.5 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.6 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Molecular Targets, 2021 & 2031F |
3.7 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Marketed Drugs, 2021 & 2031F |
3.8 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Clinical Trials, 2021 & 2031F |
3.9 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.10 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
4 Canada Gastrointestinal Diseases Drug Development Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of gastrointestinal diseases in Canada |
4.2.2 Growing demand for advanced treatment options |
4.2.3 Technological advancements in drug development for gastrointestinal diseases |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval |
4.3.2 High costs associated with research and development |
4.3.3 Limited reimbursement policies for gastrointestinal disease drugs |
5 Canada Gastrointestinal Diseases Drug Development Market Trends |
6 Canada Gastrointestinal Diseases Drug Development Market, By Types |
6.1 Canada Gastrointestinal Diseases Drug Development Market, By Disease Type |
6.1.1 Overview and Analysis |
6.1.2 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Disease Type, 2021- 2031F |
6.1.3 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Gastroenteritis, 2021- 2031F |
6.1.4 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Inflammatory Bowel Disease (IBD), 2021- 2031F |
6.1.5 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Irritable Bowel Syndrome, 2021- 2031F |
6.1.6 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Canada Gastrointestinal Diseases Drug Development Market, By Molecular Targets |
6.2.1 Overview and Analysis |
6.2.2 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Sodium Transporter NHE3 Inhibitor, 2021- 2031F |
6.2.3 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Sphinogosine-1-Phosphate Receptor Functional Antagonist, 2021- 2031F |
6.2.4 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Tumor Necrosis Factor (TNF) Blocker, 2021- 2031F |
6.2.5 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Canada Gastrointestinal Diseases Drug Development Market, By Marketed Drugs |
6.3.1 Overview and Analysis |
6.3.2 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Infliximab, 2021- 2031F |
6.3.3 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Adalimumab, 2021- 2031F |
6.3.4 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Mesalazine, 2021- 2031F |
6.3.5 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Canada Gastrointestinal Diseases Drug Development Market, By Clinical Trials |
6.4.1 Overview and Analysis |
6.4.2 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Etrolizumab, 2021- 2031F |
6.4.3 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By SHP647, 2021- 2031F |
6.4.4 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By ABX464, 2021- 2031F |
6.4.5 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By ASP3291, 2021- 2031F |
6.4.6 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Canada Gastrointestinal Diseases Drug Development Market, By Route of Administration |
6.5.1 Overview and Analysis |
6.5.2 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Oral, 2021- 2031F |
6.5.3 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Injectable, 2021- 2031F |
6.6 Canada Gastrointestinal Diseases Drug Development Market, By End-Users |
6.6.1 Overview and Analysis |
6.6.2 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.6.3 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Homecare, 2021- 2031F |
6.6.4 Canada Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
7 Canada Gastrointestinal Diseases Drug Development Market Import-Export Trade Statistics |
7.1 Canada Gastrointestinal Diseases Drug Development Market Export to Major Countries |
7.2 Canada Gastrointestinal Diseases Drug Development Market Imports from Major Countries |
8 Canada Gastrointestinal Diseases Drug Development Market Key Performance Indicators |
8.1 Number of clinical trials initiated for gastrointestinal disease drugs in Canada |
8.2 Investment in research and development for gastrointestinal disease drugs |
8.3 Adoption rate of innovative drug therapies for gastrointestinal diseases in Canada |
9 Canada Gastrointestinal Diseases Drug Development Market - Opportunity Assessment |
9.1 Canada Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
9.2 Canada Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Molecular Targets, 2021 & 2031F |
9.3 Canada Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Marketed Drugs, 2021 & 2031F |
9.4 Canada Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Clinical Trials, 2021 & 2031F |
9.5 Canada Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.6 Canada Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By End-Users, 2021 & 2031F |
10 Canada Gastrointestinal Diseases Drug Development Market - Competitive Landscape |
10.1 Canada Gastrointestinal Diseases Drug Development Market Revenue Share, By Companies, 2024 |
10.2 Canada Gastrointestinal Diseases Drug Development Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here